Related Experiment Video
Updated: Jun 12, 2026
09:17
Using Retinal Imaging to Study Dementia
Published on: November 6, 2017
Frailty as a Modifier of the Associations Between Vascular Risk Factors and Incident Dementia
Jason R Smith1, A Richey Sharrett2, James Russell Pike3
1Department of Neurology, University of North Carolina School of Medicine, Chapel Hill.
Neurology
|June 10, 2026
Summary
Late-life hypertension is linked to lower dementia risk in frail older adults but higher risk in robust individuals. This highlights the importance of considering functional status when managing blood pressure for brain health.
Area of Science:
- Gerontology
- Neurology
- Cardiovascular Medicine
Background:
- Late-life vascular risk factors' role in dementia is debated.
- Low blood pressure (BP) is linked to poor outcomes in frail individuals.
Purpose of the Study:
- To investigate the association between hypertension, diabetes, smoking, and dementia risk in robust versus frail older adults.
Main Methods:
- Prospective cohort analysis of 5,093 community-living older adults over 11 years.
- Assessed BP, diabetes, smoking, and frailty using Fried criteria.
- Used Cox proportional hazards models to estimate dementia risk, stratified by frailty status.
Main Results:
- Hypertension showed a significant interaction with frailty on dementia risk (p=0.026).
- Robust participants with hypertension had higher dementia risk (HR 1.39), while frail participants had lower risk (HR 0.82).
- Diabetes and smoking increased dementia risk in both robust and frail individuals.
Conclusions:
- Late-life hypertension's association with dementia risk differs based on functional status.
- BP management for brain health should consider age-related frailty.
Related Concept Videos
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...